H. Murooka

发表

Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase.

H. Iijima, Toshiyuki Shimizu, Yoshiko Kobayashi, 2003, Bioorganic & Medicinal Chemistry.

Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors.

Toshiyuki Shimizu, K. Kimura, T. Sakai, 2004, Bioorganic & medicinal chemistry letters.

The orally‐active and selective c‐Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen‐induced arthritis mouse model

I. Serizawa, Yasunori Uemura, K. Kubo, 2008, European journal of immunology.

Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis.

K. Nakamura, N. Nagano, S. Ohyama, 1998, General pharmacology.

The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis

Isao Serizawa, I. Serizawa, Yasunori Uemura, 2008, Journal of Neuroimmunology.

Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.

Toshiyuki Shimizu, N. Takahashi, Yoshiko Kobayashi, 2005, Journal of medicinal chemistry.

Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

D. Im, H. Nochi, Koichi Sato, 2003, Molecular pharmacology.

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

Yoshiko Kobayashi, M. Shibuya, T. Yoneda, 2006, Molecular Cancer Therapeutics.

A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation

Toshiyuki Shimizu, Yoshiko Kobayashi, M. Yagi, 1997 .

Synthesis and structure-activity relationship of Quinazoline-Urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors

M. Shibuya, N. Takahashi, Yoshiko Kobayashi, 2002 .